Acquisition by Charles Faith L of 100000 shares of Avenue Therapeutics subject to Rule 16b-3
ATXI Stock | USD 1.81 0.09 4.74% |
Under 61% of Avenue Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Avenue Therapeutics stock suggests that many investors are alarmed at this time. Avenue Therapeutics' investing sentiment shows overall attitude of investors towards Avenue Therapeutics.
Avenue |
Filed transaction by Avenue Therapeutics Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Avenue Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Avenue Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Avenue Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Avenue Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Avenue Therapeutics Fundamental Analysis
We analyze Avenue Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avenue Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avenue Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Avenue Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Avenue Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Avenue Therapeutics stock to make a market-neutral strategy. Peer analysis of Avenue Therapeutics could also be used in its relative valuation, which is a method of valuing Avenue Therapeutics by comparing valuation metrics with similar companies.
Peers
Avenue Therapeutics Related Equities
QNRX | Quoin Pharmaceuticals | 4.79 | ||||
ALLR | Allarity Therapeutics | 1.96 | ||||
WINT | Windtree Therapeutics | 0.95 | ||||
PALI | Palisade Bio | 1.39 | ||||
NRBO | Neurobo Pharmaceuticals | 2.59 | ||||
CNSP | Cns Pharmaceuticals | 2.91 | ||||
HOTH | Hoth Therapeutics | 4.53 | ||||
VRAX | Virax Biolabs | 5.52 | ||||
BDRX | Biodexa Pharmaceticals | 6.41 | ||||
REVB | Revelation Biosciences | 9.78 |
Complementary Tools for Avenue Stock analysis
When running Avenue Therapeutics' price analysis, check to measure Avenue Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avenue Therapeutics is operating at the current time. Most of Avenue Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avenue Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avenue Therapeutics' price. Additionally, you may evaluate how the addition of Avenue Therapeutics to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |